Clinic for Medical Oncology and Hematology, University of Zurich (UZH) & University Hospital Zurich (USZ), Prof. Dr. med. Dr. phil. Andreas Wicki

PhD Position in Clinical Science
100 %, temporary employment

The PhD position is embedded within the ongoing efforts to broaden the precision oncology program at the University and University Hospital in Zurich. We are currently in the process of setting up new precision oncology protocols for solid tumors and the corresponding patient cohorts. The general goal is to establish unique platforms for in-depth tumor profiling (from solid and liquid biopsies).

Your responsibilities

The new PhD student should make significant contributions to the group's activities:

At the patient level:
At the cohort level:

Your profile

What we offer

We are a clinical research group with a strong emphasis in translational research (see Irmisch et al., The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support. Cancer Cell 2021). Our efforts are aimed at bridging the gap between clinic and precision biology. Our group maintains close ties to other departments at USZ as well as to clinics and laboratories in Switzerland.

The project is linked to the PHRT Technology Transfer Project "Microchip-based circulating tumor cell profiling and drug sensitivity testing to support clinical decisions in metastatic cancer patients".

For medical doctors there is the option to fullfill 20% of clinical work within the employment as PhD Student. The PhD program in Clinical Science offers an interessting curriculum providing skills in Epidemiology and Biostatistics. A variety of additional courses e.g. on academic writing or presentation skills are available.

Place of work

University Hospital Zurich, Rämistrasse 100, 8091 Zurich

Start of employment

The preferred employment start date is February 1, 2022 or to be mutually agreed. Please submit your application by December 1, 2021. Interviews with the candidates are planned for the beginning of January 2022.

Further information